IGF-1 LR3 stimulates fetal heart growth while preserving coronary vascular supply and function in sheep
Background
In many forms of heart disease, a primary challenge is the loss of contractile function, which is often linked to an insufficient number of cardiomyocytes (heart muscle cells). A key therapeutic goal is to expand the heart's cardiomyocyte endowment before birth, but this must be paired with a proportional increase in the coronary vascular supply to nourish the larger muscle mass. Without adequate blood flow, any gains in heart size would be functionally useless and potentially detrimental. Insulin-like Growth Factor 1 (IGF-1) is known to stimulate fetal cardiomyocyte proliferation and increase heart mass. However, its effect on the coronary vasculature—the network of arteries supplying the heart muscle itself—was previously unknown, representing a critical gap in understanding its therapeutic potential for congenital heart resilience.
Study Design
The study used a near-term fetal sheep model. Pregnant ewes underwent surgery to instrument the fetuses, which were then studied between 127 and 134 days of gestation (full term is 147 days). The fetuses received a continuous infusion of either IGF-1 LR3 or a saline vehicle (Control). To assess the coronary system, researchers measured pressure-flow relationships to model the physical determinants of coronary blood flow. They also induced an episode of acute hypoxia (low oxygen) and administered a progressive blockade of adenosine receptors and nitric oxide synthase to probe the mechanisms of vasodilation under stress. The primary endpoint was to determine if coronary growth and function matched the IGF-1-induced myocardial growth.
Results
The primary finding was that IGF-1-stimulated fetal myocardial growth was accompanied by a proportional expansion of the coronary vasculature. Coronary conductance, a measure of how easily blood flows through the vessels, was preserved on a per-gram basis after IGF-1 LR3 treatment, meaning the new heart tissue was just as well-supplied as in control animals. During induced hypoxia, the mechanisms of coronary vasodilation were functionally identical between groups; the contributions of both adenosine and nitric oxide to increasing blood flow were similar in IGF-1-treated and Control fetuses.
The relationships between coronary flow and blood oxygen contents were also found to be similar between the two groups, indicating that the vascular response to metabolic demand was not compromised by the accelerated growth. This demonstrates that the coronary system not only grew in size to match the larger heart but also maintained its crucial functional responsiveness to physiological stressors like low oxygen.
Key Findings
- IGF-1-stimulated fetal myocardial growth is matched by appropriate expansion of the coronary vasculature.
- Coronary conductance per gram of heart tissue was preserved following IGF-1 LR3 treatment.
- Adenosine and nitric oxide contributed similarly to hypoxia-mediated coronary vasodilation in both IGF-1 and control groups.
- The relationship between coronary flow and blood oxygen content was similar between groups, indicating normal functional response.
Why It Matters
These findings suggest that IGF-1 LR3 could be a viable strategy to safely increase both heart muscle and its supporting blood supply before birth. For potential therapeutic applications aimed at improving congenital heart resilience, this is a crucial piece of the puzzle. It shows that IGF-1 doesn't just create a larger, under-supplied heart; it promotes balanced, functional growth. This bolsters the case for IGF-1 as a potential intervention to enhance cardiac endowment, potentially mitigating the long-term effects of conditions that compromise heart function from birth. While this is an animal study, it provides foundational evidence that the induced growth is healthy and sustainable, a key step before considering any potential human applications. The protocol doesn't just add muscle; it builds the necessary infrastructure alongside it.
